News

Hure details what clinicians need to know to protect their patients.

Discover how gene expression profiling transforms melanoma and SCC management, enhancing personalized treatment strategies and improving patient outcomes in skin cancer care.

The DERM 2025 midway recap includes tips for atopic dermatitis, chronic hand eczema, and pruritus.

Rheumatologist Karim Ladak, MD, shared diagnostic and treatment tips for cutaneous lupus at DERM 2025.

Catch up on coverage from the first day of the 2025 Elevate-Derm Summer Conference held in Park City, Utah.

Catch up on coverage from the first day of the 50th Annual Society for Pediatric Dermatology Meeting in Seattle, Washington.

Explore the INTEGUMENT-INFANT study, assessing roflumilast cream's safety and efficacy for infants with atopic dermatitis in a groundbreaking trial.

Walter Liszewski, MD, highlights the clinical impact of patch testing and shares strategies for selecting and dosing JAK inhibitors at Elevate-Derm Summer.

Discover innovative research pearls at the Elevate-Derm Summer Conference 2025, focusing on psoriasis, skin cancer, and more.

Discover insights from SPD 2025 on pediatric obesity treatment, emphasizing multidisciplinary care and innovative therapies.

New findings at Elevate Derm highlight remibrutinib's rapid and sustained efficacy in reducing chronic spontaneous urticaria symptoms, offering hope for patients.

Psoriasis in high impact areas responded well to icotrokinra, presenting a potential exciting option for patients.

At the DERM 2025 conference, Scott Boswell, MD, shares tips for combining therapies.

James Song, MD, discussed his UnlIMMited DERM 2025 poster detailing risankizumab's efficacy for genital and scalp psoriasis.

The approval makes delgocitinib cream the first and only approved therapy in the US for CHE in adults.

Join Dermatology Times at the 2025 Elevate-Derm Summer Conference for expert insights and live updates from Park City, Utah.

Joe Gorelick, MSN, FNP-C, discusses upcoming highlights and new data expected at the upcoming DERM 2025 CME Conference.

Jacob Thyssen, PhD, discusses tralokinumab's promising results for hand eczema, highlighting its potential to transform treatment options for patients.

Castle Biosciences’ DecisionDx-Melanoma test plays a role in melanoma management with precise risk stratification, enhancing patient outcomes and reducing unnecessary surgeries.

Tildrakizumab, HCP-administered biologics, and lifestyle-based decision-making took center stage in an interactive discussion led by Omar Noor, MD, FAAD, and colleagues.

We want to know: Will you be attending the conference in Seattle this week?

This review of the latest dermatologic studies includes insights into pruritus as an indicator for QoL in CTCL, the research landscape of acquired dermal macular hyperpigmentation, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Updated research finds that chronic stress disrupts healing processes and scar treatments, limiting the effectiveness of wound care in some patients.

Lars French, MD, explains how the new WHA resolution on skin health could drive training, access, and global policy change.

A new WHA resolution spotlights skin health, pushing member states to close care gaps and integrate dermatology into public health.

Sun Pharma reveals promising phase 3 results for tildrakizumab (Ilumya) in treating PsA, showing significant symptom improvement in patients.

Matthew Zirwas, MD, discusses the complexities of safety analysis in psoriasis clinical trials, advocating for exposure-adjusted incidence rates to enhance risk communication.

Social media spreads significant retinol misinformation, risking adolescent skin health. Experts call for improved digital education and accurate content creation.